PBDA Stock Overview A biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Protalix BioTherapeutics, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Protalix BioTherapeutics Historical stock prices Current Share Price US$2.13 52 Week High US$2.20 52 Week Low US$0.64 Beta 0.71 1 Month Change 30.35% 3 Month Change 178.50% 1 Year Change 39.67% 3 Year Change 173.08% 5 Year Change -34.26% Change since IPO -90.66%
Recent News & Updates
Protalix BioTherapeutics, Inc. to Report Q3, 2024 Results on Nov 14, 2024 Nov 07
Protalix BioTherapeutics, Inc. to Report Q2, 2024 Results on Aug 14, 2024 Aug 07 Protalix BioTherapeutics, Inc.(NYSEAM:PLX) dropped from Russell Small Cap Comp Value Index
Protalix BioTherapeutics, Inc. to Report Q1, 2024 Results on May 10, 2024 May 05
Protalix BioTherapeutics, Inc., Annual General Meeting, Jun 27, 2024 May 01
Protalix BioTherapeutics, Inc. to Report Fiscal Year 2023 Results on Mar 14, 2024 Mar 08 See more updates
Protalix BioTherapeutics, Inc. to Report Q3, 2024 Results on Nov 14, 2024 Nov 07
Protalix BioTherapeutics, Inc. to Report Q2, 2024 Results on Aug 14, 2024 Aug 07 Protalix BioTherapeutics, Inc.(NYSEAM:PLX) dropped from Russell Small Cap Comp Value Index
Protalix BioTherapeutics, Inc. to Report Q1, 2024 Results on May 10, 2024 May 05
Protalix BioTherapeutics, Inc., Annual General Meeting, Jun 27, 2024 May 01
Protalix BioTherapeutics, Inc. to Report Fiscal Year 2023 Results on Mar 14, 2024 Mar 08
Protalix BioTherapeutics, Inc. to Report Q3, 2023 Results on Nov 06, 2023 Oct 31
Protalix Biotherapeutics Appoints Eliot Richard Forster to Succeed Zeev Bronfeld as Chairman, Effective as of September 14, 2023 Sep 14
Protalix BioTherapeutics, Inc. to Report Q2, 2023 Results on Aug 07, 2023 Aug 01
Protalix BioTherapeutics, Inc., Annual General Meeting, Jun 28, 2023 May 19
Chiesi Global Rare Diseases and Protalix Biotherapeutics, Inc. Announce FDA Approval of ELFABRIO® (pegunigalsidase alfa-iwxj) for the Treatment of Fabry Disease May 11
Protalix Biotherapeutics, Inc. and Chiesi Global Rare Diseases Announces European Commission Grants Marketing Authorization to PRX-102 (Pegunigalsidase Alfa) for the Treatment of Adult Patients with Fabry Disease May 06 Protalix BioTherapeutics to Delist Its Common Stock from the Tel Aviv Stock Exchange Dec 23
Protalix Biotherapeutics and Chiesi Global Rare Diseases Announce U.S. Food and Drug Administration Acceptance of A Resubmitted Biologics License Application for Pegunigalsidase Alfa for the Proposed Treatment of Fabry Disease Dec 06
Third quarter 2022 earnings released: US$0.072 loss per share (vs US$0.092 loss in 3Q 2021) Nov 16
Protalix BioTherapeutics, Inc. and Chiesi Global Rare Diseases Announces Resubmission of Biologics License Application to U.S. Food and Drug Administration for Pegunigalsidase Alfa for the Treatment of Fabry Disease Nov 15
Protalix BioTherapeutics, Inc. to Report Q3, 2022 Results on Nov 14, 2022 Nov 08
Second quarter 2022 earnings released: US$0.11 loss per share (vs US$0.25 loss in 2Q 2021) Aug 17
Protalix BioTherapeutics, Inc. to Report Q2, 2022 Results on Aug 15, 2022 Aug 09
Protalix BioTherapeutics, Inc. Appoints Shmuel "Muli" Ben Zvi to Its Board of Directors and Audit Committee and Compensation Committee Jul 01
First quarter 2022 earnings released: US$0.05 loss per share (vs US$0.14 loss in 1Q 2021) May 17 Protalix BioTherapeutics, Inc. to Report Q1, 2022 Results on May 16, 2022 May 10
President recently bought €94k worth of stock Apr 14
Protalix Biotherapeutics, Inc. Announces Topline Results from BALANCE Pivotal Phase III Clinical Trial Evaluating pegunigalsidase alfa Apr 05
Full year 2021 earnings released: US$0.63 loss per share (vs US$0.22 loss in FY 2020) Apr 01
Protalix BioTherapeutics, Inc. and Chiesi Global Rare Diseases Announces Submission of Marketing Authorization Application to the European Medicines Agency for PRX-102 for Treatment of Fabry Disease Feb 25
Third quarter 2021 earnings released: US$0.092 loss per share (vs US$0.14 loss in 3Q 2020) Nov 16
Third quarter 2021 earnings released: US$0.092 loss per share (vs US$0.14 loss in 3Q 2020) Nov 16
Second quarter 2021 earnings released: US$0.25 loss per share (vs US$0.13 loss in 2Q 2020) Aug 18
Protalix BioTherapeutics, Inc. Announces Submission of Type A Meeting Request to the FDA Aug 04
Protalix BioTherapeutics, Inc. and Chiesi Global Rare Diseases Provide Update Regarding Clinical Development of PRX-102 for Treatment of Fabry Disease Jun 03
Forecast breakeven pushed back to 2022 May 15
First quarter 2021 earnings released: US$0.14 loss per share (vs US$0.096 profit in 1Q 2020) May 15
Protalix Biotherapeutics and Chiesi Global Rare Diseases Receive Complete Response Letter for Pegunigalsidase Alfa from Fda Apr 29
Full year 2020 earnings released: US$0.22 loss per share (vs US$1.23 loss in FY 2019) Apr 02
Protalix BioTherapeutics, Inc. and Chiesi Global Rare Diseases Announces Positive Topline Results from Bright Phase III Open-Label, Switch-Over Clinical Trial Evaluating Pegunigalsidase Alfa 2 Mg/Kg Every Four Weeks for Treatment of Fabry Disease Feb 24
Protalix Biotherapeutics Enters into an Exclusive Partnership with Sarcomed USA to Develop Alidornase Alfa for the Treatment of Pulmonary Sarcoidosis and Related Respiratory Diseases Via Inhaled Delivery Feb 13
Protalix BioTherapeutics and Chiesi Global Rare Diseases Present Key Clinical Data of Pegunigalsidase Alfa for the Treatment of Fabry Disease at the 17th Annual WORLDSymposium™ 2021 Feb 11
New 90-day high: €3.74 Feb 05
Protalix BioTherapeutics Announces Presentations at the 17th Annual WORLDSymposium™ 2021 Feb 02
New 90-day high: €3.44 Jan 16
Protalix Biotherapeutics and Chiesi Global Rare Diseases Announce Final Results of Bridge Phase III Open-Label, Switch-Over Clinical Trial Evaluating Pegunigalsidase Alfa for the Treatment of Fabry Disease Dec 31
Protalix Biotherapeutics and Chiesi Global Rare Diseases Announces Extension of Pdufa Date for Pegunigalsidase Alfa for the Propose Treatment of Fabry Disease Nov 29
Third quarter earnings released Oct 30
New 90-day low: €2.76 Oct 30
Chiesi Farmaceutici S.P.A. and Protalix BioTherapeutics, Inc Announce Launch of an Expanded Access Program (Eap) in the United States for Pegunigalsidase Alfa for the Proposed Treatment of Fabry Disease Oct 03
Protalix Biotherapeutics and Chiesi Farmaceutici Announce Successful Pre-BLA Meeting with FDA for Accelerated Approval of Pegunigalsidase Alfa for the Treatment of Fabry Disease in the United States Sep 25
New 90-day low - €2.82 Sep 10
Protalix Biotherapeutics Regains Compliance with NYSE American Continued Listing Standards Sep 09
New 90-day low - €2.88 Sep 04
First half earnings released Aug 10
Protalix BioTherapeutics, Inc. to Report Q2, 2020 Results on Aug 10, 2020 Aug 04 Shareholder Returns PBDA DE Biotechs DE Market 7D 22.9% 5.8% 2.0% 1Y 39.7% -6.1% 9.6%
See full shareholder returns
Return vs Market: PBDA exceeded the German Market which returned 9.6% over the past year.
Price Volatility Is PBDA's price volatile compared to industry and market? PBDA volatility PBDA Average Weekly Movement 11.4% Biotechs Industry Average Movement 7.4% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.7% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: PBDA's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: PBDA's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases.
Show more Protalix BioTherapeutics, Inc. Fundamentals Summary How do Protalix BioTherapeutics's earnings and revenue compare to its market cap? PBDA fundamental statistics Market cap €159.89m Earnings (TTM ) -€9.31m Revenue (TTM ) €44.27m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) PBDA income statement (TTM ) Revenue US$45.67m Cost of Revenue US$29.29m Gross Profit US$16.38m Other Expenses US$25.98m Earnings -US$9.61m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -0.13 Gross Margin 35.86% Net Profit Margin -21.03% Debt/Equity Ratio 0%
How did PBDA perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/08 00:43 End of Day Share Price 2025/01/08 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Protalix BioTherapeutics, Inc. is covered by 10 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Ritu Baral Canaccord Genuity Difei Yang Capstone Investments Peter Welford Jefferies LLC
Show 7 more analysts 
